Genetic investigations in cerebral palsy.
Journal
Developmental medicine and child neurology
ISSN: 1469-8749
Titre abrégé: Dev Med Child Neurol
Pays: England
ID NLM: 0006761
Informations de publication
Date de publication:
29 Aug 2024
29 Aug 2024
Historique:
revised:
23
07
2024
received:
08
05
2024
accepted:
29
07
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
aheadofprint
Résumé
The original description of cerebral palsy (CP) contained case histories suggesting that perinatal environmental stressors resulted in brain injury and neurodevelopmental disability. While there are clear associations between environmental impact on brain development and CP, recent studies indicate an 11% to 40% incidence of monogenic conditions in patients given a diagnosis of CP. A genetic diagnosis supports the delivery of personalized medicine. In this review, we describe how the Wnt pathway exemplifies our understanding of pathophysiology related to a gene variant (CTNNB1) found in some children diagnosed with CP. We cover studies undertaken to establish the baseline prevalence of monogenic conditions in populations attending CP clinics. We list factors indicating increased likelihood of a genomic diagnosis; and we highlight the need for a comprehensive, accurate, genotype-phenotype reference data set to aid variant interpretation in CP cohorts. We also consider the wider societal implications of genomic management of CP including significance of the diagnostic label, benefits and pitfalls of a genetic diagnosis, logistics, and cost.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Developmental Medicine & Child Neurology published by John Wiley & Sons Ltd on behalf of Mac Keith Press.
Références
Little W. On the influence of abnormal parturition, difficult labours, premature birth, and asphyxia neonatorum, on the mental and physical condition of the child, especially in relation to deformities. Trans Obstet Soc 1861: 293.
Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D, et al. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl 2007; 109: 8–14.
MacLennan AH, Lewis S, Moreno‐De‐Luca A, Fahey M, Leventer RJ, McIntyre S, et al. Genetic or Other Causation Should Not Change the Clinical Diagnosis of Cerebral Palsy. J Child Neurol 2019; 34: 472–6.
Dan B. A new description of cerebral palsy: Framing, wording, and perspective. Developmental Medicine & Child Neurology 2024; 66: 822–3.
Arnaud C, Ehlinger V, Delobel‐Ayoub M, Klapouszczak D, Perra O, Hensey O, et al. Trends in Prevalence and Severity of Pre/Perinatal Cerebral Palsy Among Children Born Preterm From 2004 to 2010: A SCPE Collaboration Study. Front Neurol 2021; 12: 624884.
Smithers‐Sheedy H, Waight E, Goldsmith S, Reid S, Gibson C, Watson L, et al. Declining trends in birth prevalence and severity of singletons with cerebral palsy of prenatal or perinatal origin in Australia: A population‐based observational study. Dev Med Child Neurol 2022; 64: 1114–22.
McIntyre S, Goldsmith S, Webb A, Ehlinger V, Hollung SJ, McConnell K, et al. Global prevalence of cerebral palsy: A systematic analysis. Dev Med Child Neurol 2022; 64: 1494–506.
Silbereis JC, Huang EJ, Back SA, Rowitch DH. Towards improved animal models of neonatal white matter injury associated with cerebral palsy. Dis Model Mech 2010; 3: 678–88.
Dorner RA, Burton VJ, Allen MC, Robinson S, Soares BP. Preterm neuroimaging and neurodevelopmental outcome: a focus on intraventricular hemorrhage, post‐hemorrhagic hydrocephalus, and associated brain injury. Journal of Perinatology 2018; 38: 1431–43.
de Vries LS, Jongmans MJ. Long‐term outcome after neonatal hypoxic‐ischaemic encephalopathy. Archives of Disease in Childhood ‐ Fetal and Neonatal Edition 2010; 95: F220.
Dunbar M, Mineyko A, Hill M, Hodge J, Floer A, Kirton A. Population Based Birth Prevalence of Disease‐Specific Perinatal Stroke. Pediatrics 2020; 146.
Goldsmith S, McIntyre S, Scott H, Himmelmann K, Smithers‐Sheedy H, Andersen GL, et al. Congenital anomalies in children with postneonatally acquired cerebral palsy: an international data linkage study. Developmental Medicine & Child Neurology 2021; 63: 421–8.
Lu QR, Yuk D, Alberta JA, Zhu Z, Pawlitzky I, Chan J, et al. Sonic hedgehog‐‐regulated oligodendrocyte lineage genes encoding bHLH proteins in the mammalian central nervous system. Neuron 2000; 25: 317–29.
Billiards SS, Haynes RL, Folkerth RD, Borenstein NS, Trachtenberg FL, Rowitch DH, et al. Myelin abnormalities without oligodendrocyte loss in periventricular leukomalacia. Brain Pathol 2008; 18: 153–63.
Fancy SP, Baranzini SE, Zhao C, Yuk DI, Irvine KA, Kaing S, et al. Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev 2009; 23: 1571–85.
Fancy SP, Harrington EP, Yuen TJ, Silbereis JC, Zhao C, Baranzini SE, et al. Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination. Nat Neurosci 2011; 14: 1009–16.
Yuen TJ, Silbereis JC, Griveau A, Chang SM, Daneman R, Fancy SPJ, et al. Oligodendrocyte‐encoded HIF function couples postnatal myelination and white matter angiogenesis. Cell 2014; 158: 383–96.
Kayumi S, Pérez‐Jurado LA, Palomares M, Rangu S, Sheppard SE, Chung WK, et al. Genomic and phenotypic characterization of 404 individuals with neurodevelopmental disorders caused by CTNNB1 variants. Genet Med 2022; 24: 2351–66.
Fancy SP, Harrington EP, Baranzini SE, Silbereis JC, Shiow LR, Yuen TJ, et al. Parallel states of pathological Wnt signaling in neonatal brain injury and colon cancer. Nat Neurosci 2014; 17: 506–12.
Jin SC, Lewis SA, Bakhtiari S, Zeng X, Sierant MC, Shetty S, et al. Mutations disrupting neuritogenesis genes confer risk for cerebral palsy. Nat Genet 2020; 52: 1046–56.
Fahey MC, Maclennan AH, Kretzschmar D, Gecz J, Kruer MC. The genetic basis of cerebral palsy. Dev Med Child Neurol 2017; 59: 462–9.
Chopra M, Gable DL, Love‐Nichols J, Tsao A, Rockowitz S, Sliz P, et al. Mendelian etiologies identified with whole exome sequencing in cerebral palsy. Ann Clin Transl Neurol 2022; 9: 193–205.
Srivastava S, Lewis SA, Cohen JS, Zhang B, Aravamuthan BR, Chopra M, et al. Molecular Diagnostic Yield of Exome Sequencing and Chromosomal Microarray in Cerebral Palsy: A Systematic Review and Meta‐analysis. JAMA Neurol 2022; 79: 1287–95.
Gonzalez‐Mantilla PJ, Hu Y, Myers SM, Finucane BM, Ledbetter DH, Martin CL, Moreno‐De‐Luca A. Diagnostic Yield of Exome Sequencing in Cerebral Palsy and Implications for Genetic Testing Guidelines: A Systematic Review and Meta‐analysis. JAMA Pediatr 2023; 177: 472–8.
Takezawa Y, Kikuchi A, Haginoya K, Niihori T, Numata‐Uematsu Y, Inui T, et al. Genomic analysis identifies masqueraders of full‐term cerebral palsy. Ann Clin Transl Neurol 2018; 5: 538–51.
Smedley D, Jacobsen JO, Jäger M, Köhler S, Holtgrewe M, Schubach M, et al. Next‐generation diagnostics and disease‐gene discovery with the Exomiser. Nat Protoc 2015; 10: 2004–15.
England N. National genomic test directory. See ‘National genomic test directory for rare and inherited diseases’ and ‘eligibility criteria document' at https://www.england.nhs.uk/publication/national‐genomic‐test‐directories/ (last checked 11 June 2023) 2023.
Martin AR, Williams E, Foulger RE, Leigh S, Daugherty LC, Niblock O, et al. PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels. Nat Genet 2019; 51: 1560–5.
Sinibaldi L, Garone G, Mandarino A, Iarossi G, Chioma L, Dentici ML, et al. Congenital heart defects in CTNNB1 syndrome: Raising clinical awareness. Clinical Genetics 2023; 104: 528–41.
Kharbanda M, Pilz DT, Tomkins S, Chandler K, Saggar A, Fryer A, et al. Clinical features associated with CTNNB1 de novo loss of function mutations in ten individuals. European Journal of Medical Genetics 2017; 60: 130–5.
Köhler S, Gargano M, Matentzoglu N, Carmody LC, Lewis‐Smith D, Vasilevsky NA, et al. The Human Phenotype Ontology in 2021. Nucleic Acids Res 2021; 49: D1207‐d17.
Gargano MA, Matentzoglu N, Coleman B, Addo‐Lartey EB, Anagnostopoulos AV, Anderton J, et al. The Human Phenotype Ontology in 2024: phenotypes around the world. Nucleic Acids Res 2024; 52: D1333‐d46.
Horber V, Grasshoff U, Sellier E, Arnaud C, Krägeloh‐Mann I, Himmelmann K. The Role of Neuroimaging and Genetic Analysis in the Diagnosis of Children With Cerebral Palsy. Front Neurol 2020; 11: 628075.
Janzing AM, Eklund E, De Koning TJ, Eggink H. Clinical Characteristics Suggestive of a Genetic Cause in Cerebral Palsy: A Systematic Review. Pediatr Neurol 2024; 153: 144–51.
Werkhoven S, Anderson JH, Robeyns IAM. Who benefits from diagnostic labels for developmental disorders? Dev Med Child Neurol 2022; 64: 944–9.
Zagaglia S, Selch C, Nisevic JR, Mei D, Michalak Z, Hernandez‐Hernandez L, et al. Neurologic phenotypes associated with COL4A1/2 mutations: Expanding the spectrum of disease. Neurology 2018; 91: e2078‐e88.
van Eyk CL, Fahey MC, Gecz J. Redefining cerebral palsies as a diverse group of neurodevelopmental disorders with genetic aetiology. Nat Rev Neurol 2023; 19: 542–55.
Smithers‐Sheedy H, Badawi N, Blair E, Cans C, Himmelmann K, Krägeloh‐Mann I, et al. What constitutes cerebral palsy in the twenty‐first century? Dev Med Child Neurol 2014; 56: 323–8.
Pham R, Mol BW, Gecz J, MacLennan AH, MacLennan SC, Corbett MA, et al. Definition and diagnosis of cerebral palsy in genetic studies: a systematic review. Dev Med Child Neurol 2020; 62: 1024–30.
Low KJ, Watford A, Blair PS, Nabney I, Powell J, Wynn SL, et al. Improving the care of children with GENetic Rare disease: Observational Cohort study (GenROC): a study protocol. medRxiv 2024: 2024.02.23.24303131.
Holborn MA, Ford G, Turner S, Mellet J, van Rensburg J, Joubert F, Pepper MS. The NESHIE and CP Genetics Resource (NCGR): A database of genes and variants reported in neonatal encephalopathy with suspected hypoxic ischemic encephalopathy (NESHIE) and consequential cerebral palsy (CP). Genomics 2022; 114: 110508.
Brittain HK, Scott R, Thomas E. The rise of the genome and personalised medicine. Clin Med (Lond) 2017; 17: 545–51.
Stark Z, Ellard S. Rapid genomic testing for critically ill children: time to become standard of care? European Journal of Human Genetics 2022; 30: 142–9.
Chung CC, Leung GK, Mak CC, Fung JL, Lee M, Pei SL, et al. Rapid whole‐exome sequencing facilitates precision medicine in paediatric rare disease patients and reduces healthcare costs. The Lancet Regional Health–Western Pacific 2020; 1.
Low KJ, Watford A, Blair P, Nabney I, Powell J, Wynn SL, et al. Improving the care of children with GENetic Rare disease: Observational Cohort study (GenROC)‐a study protocol. BMJ Open 2024; 14: e085237.
Smithers‐Sheedy H, Henry G. What does an aetiological diagnosis actually mean? Developmental Medicine & Child Neurology 2022; 64: 675–6.
French CE, Dolling H, Mégy K, Sanchis‐Juan A, Kumar A, Delon I, et al. Refinements and considerations for trio whole‐genome sequence analysis when investigating Mendelian diseases presenting in early childhood. HGG Adv 2022; 3: 100113.
Fehlings DL, Zarrei M, Engchuan W, Sondheimer N, Thiruvahindrapuram B, MacDonald JR, et al. Comprehensive whole‐genome sequence analyses provide insights into the genomic architecture of cerebral palsy. Nature genetics 2024; 56: 585–94.
May HJ, Fasheun JA, Bain JM, Baugh EH, Bier LE, Revah‐Politi A, et al. Genetic testing in individuals with cerebral palsy. Developmental Medicine & Child Neurology 2021; 63: 1448–55.